Contracting malaria during pregnancy – especially a first pregnancy – can lead to a severe, placental form of the disease that is often fatal. Red blood cells infected with the malaria parasite Plasmodium falciparum display a protein, VAR2CSA, which can recognize and bind CSA molecules present on placental cells and in placental blood spaces. This leads to the infected blood cells accumulating in the placenta and inducing harmful inflammation.

Having been exposed to the parasite in prior pregnancies generates antibodies that target VAR2CSA, stopping the infected blood cells from latching onto placental CSA or tagging them for immune destruction. Overall, this makes placental malaria less severe in following pregnancies, and suggests that vaccines could be developed based on VAR2CSA.

However, this protein has regions that can vary in structure, meaning that P. falciparaum can generate many VAR2CSA variants. Individuals exposed to the parasite naturally generate antibodies that block a wide array of variants from attaching to CSA. In contrast, first-generation vaccines based on VAR2CSA fragments have only induced variant-specific antibodies, therefore offering limited protection against infection.

As a response, Doritchamou et al. set out to find VAR2CSA structures that could be recognized by antibodies targeting an array of variants. Blood was obtained from women who had had multiple pregnancies and were immune to malaria. Their plasma was passed over five different large VAR2CSA variants in order to isolate and purify antibodies that attached to these structures.

Doritchamou et al. found that antibodies binding to individual VAR2CSA structures could also recognise a wide array of VAR2CSA variants and blocked all tested parasites from sticking to CSA. While further research is needed, these findings highlight antibodies that cross-react to diverse VAR2CSA variants and could be used to design more effective vaccines targeting placental malaria.

Plasmodium falciparum infection in pregnant women causes placental malaria (PM) when P. falciparum-infected erythrocytes (IE) accumulate in the intervillous spaces of the placenta. PM has been linked to several adverse pregnancy outcomes (Steketee et al., 2001; Guyatt and Snow, 2001; Desai et al., 2007; Moore et al., 2017), and first-time mothers are most vulnerable (Brabin, 1983). Over successive pregnancies, PM and the related sequalae become less prevalent (Guyatt and Snow, 2001). Susceptibility to PM has been attributed to P. falciparum parasites that bind chondroitin sulphate-A (CSA) expressed by the placental syncytiotrophoblast (Fried and Duffy, 1996), and express the variant surface antigen VAR2CSA (Salanti et al., 2003; Tuikue Ndam et al., 2005). Conversely, the decrease in PM-related poor pregnancy outcomes with increasing parity is associated with the acquisition of functional antibodies to CSA-binding IE (Fried and Duffy, 1998; Ricke et al., 2000) and antibodies to VAR2CSA (Salanti et al., 2004; Ndam et al., 2015). Such functional antibodies have been characterized for two major functions: (1) blocking CSA-binding of VAR2CSA-expressing parasites and (2) opsonizing IE to promote phagocytosis (Fried and Duffy, 1998; Ricke et al., 2000; Duffy and Fried, 2003; Keen et al., 2007; Ataíde et al., 2011).

Hence, VAR2CSA represents the leading candidate for PM vaccine development. VAR2CSA is a large (∼318–478 kDa) multidomain transmembrane protein, a member of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family encoded by var genes (Gardner et al., 2002; Hviid and Jensen, 2015). The cysteine-rich ectodomain is formed by N-terminal sequence (NTS), six and sometimes more Duffy-binding-like (DBL) domains as well as interdomain (ID) regions (Kraemer and Smith, 2006; Doritchamou et al., 2019). Recent studies showed that VAR2CSA ectodomain structure includes a stable core (NTS-DBL1X-ID1-DBL2X-ID2-DBL3X-DBL4e-ID3) flanked by a flexible arm (DBL5e -DBL6e), and the receptor interaction involves CSA threading through two channels that formed within the stable core (Ma et al., 2021; Wang et al., 2021). Multiple individual DBL domains of VAR2CSA interact with CSA in vitro (Dahlbäck et al., 2011; Clausen et al., 2012; Ma et al., 2021) and induce functional antibodies in animals (Bigey et al., 2011; Fried et al., 2013; Nielsen and Salanti, 2015; Chêne et al., 2018). Two subunit vaccine candidates (called PAMVAC and PRIMVAC) from the N-terminal region of VAR2CSA were recently tested in phase one trials (Mordmüller et al., 2019; Sirima et al., 2020). Both trial teams reported that VAR2CSA subunit vaccines were safe, immunogenic and induced functional anti-adhesion antibodies in malaria-naive and malaria-exposed women (Mordmüller et al., 2019; Sirima et al., 2020). However, functional activity was primarily against homologous parasites (same VAR2CSA sequence as vaccine) and low or absent against heterologous parasites (Sirima et al., 2020), suggesting the vaccine antigen failed to display functional epitopes shared across multiple P. falciparum variants (reviewed in Doritchamou et al., 2021).

Similarly, VAR2CSA fragments (single or double domains) fail to purify the broadly neutralizing activity of sera from PM-resistant multigravidae (Doritchamou et al., 2016). Although VAR2CSA fragments (including constructs similar to PAMVAC vaccine) purified antibodies with CSA-binding inhibitory activity against homologous parasites, broadly neutralizing activity was neither purified nor depleted after passing sera over several VAR2CSA domains and variants (Doritchamou et al., 2016). These data supports the hypothesis that functional antibodies to VAR2CSA may target conformational epitopes not displayed by any individual domain: for example, the strain-transcending human monoclonal antibody PAM1.4 is specific for an unknown conformational epitope on full-length VAR2CSA (Barfod et al., 2007).

Naturally acquired antibodies of multiparous women exhibit broadly neutralizing anti-adhesion activity (Fried and Duffy, 1998; Ricke et al., 2000; Ndam et al., 2015). However, it is unknown whether broadly binding-inhibitory antibodies target conserved epitopes on VAR2CSA or rather result from the cumulative repertoire of antibodies against variant-specific epitopes. In this study, we investigate the hypothesis that full-length VAR2CSA ectodomain may capture naturally acquired antibodies from multigravidae plasma with greater breadth of neutralizing activity than previously achieved by multiple VAR2CSA domains. We show that a single ectodomain can purify strain-transcending IgG as well as the bulk of functional activity naturally acquired by multigravid women. In parallel, the depletion of IgG reactivities to five variants of full-length VAR2CSA resulted in significantly diminished strain-transcending anti-adhesion activity. These data suggest that full-length VAR2CSA ectodomain displays functional epitopes that are absent in subunit VAR2CSA fragments and provide a basis to design improved vaccines.

VAR2CSA is the leading vaccine candidate to protect malaria-exposed pregnant women against PM and related adverse outcomes. Two vaccines based on VAR2CSA fragments have been recently tested in clinical trials (Mordmüller et al., 2019; Sirima et al., 2020), showing good safety and immunogenicity but a general inability to induce broadly neutralizing antibodies, such as those described in sera of PM-resistant multigravid women (Fried and Duffy, 1998; Ricke et al., 2000; Duffy and Fried, 2003; Ndam et al., 2015). The limitations of VAR2CSA domain-based subunit vaccines have also been established from the studies of naturally acquired antibodies in PM-resistant multigravidae, where single domains or domain combinations from different variants failed to deplete heterologous binding-inhibition activity (Doritchamou et al., 2016). Among the probable explanations, the restricted array of protective epitopes displayed by VAR2CSA subunit vaccines, as well as the contribution of antibodies targeting other variants or antigens (including non-VAR2CSA proteins), are of major interest. It is therefore likely that larger fragments of VAR2CSA would offer a broader spectrum of functional epitopes including conformational epitopes and those present in other fragments missing from the subunits tested. Supporting this hypothesis, the present data demonstrate that strain-transcending naturally acquired anti-adhesion antibodies can be purified on a single recombinant VAR2CSA ectodomain, providing additional evidence that define VAR2CSA as the major target of functional antibodies.

This conclusion is well-supported by previous studies showing that naturally acquired anti-adhesion antibodies in PM target VAR2CSA (Bigey et al., 2011; Doritchamou et al., 2016), even though other invariant proteins are highly expressed by placental parasites (Francis et al., 2007; Fried et al., 2007; Tuikue Ndam et al., 2008; Bertin et al., 2013). Anti-adhesion activity of antibodies targeting these invariant proteins has not been reported thus far, and whether these proteins play a role in parasite binding to CSA is still unclear. Our data demonstrate that the removal of IgG specific to five variants of VAR2CSA ectodomain significantly reduced/abolished IE-surface reactivity and the CSA-binding inhibition activity of total IgG from multigravidae. This observation suggests that antibodies to surface-expressed non-VAR2CSA proteins might have limited or no blocking activity against CSA-binding parasites, although a synergistic effect of these antibodies with anti-VAR2CSA cannot be excluded.

Naturally acquired antibodies of malaria-exposed multigravid women recognize placenta-binding parasites from diverse geographical origins (Fried and Duffy, 1998; Ricke et al., 2000). One leading hypothesis is that pregnant women acquire antibodies to both cross-reactive and variant-specific epitopes over successive pregnancies and exposure to diverse placenta-binding parasites. We show here that the purification of IgG to VAR2CSA recombinants resulted in loss of IE surface reactivity against the three homologous parasites, and significantly reduced heterologous cross-reactivity of total IgG to maternal isolates. Consequently, the VAR2CSA-purified IgG exhibited strong cross reactivity to all isolates tested in this study, with IgG purified on the first variant demonstrating the highest level of cross-reactivity to diverse CSA-binding isolates. Of note, the isolates under study included WF12/7G8 that expresses the South American VAR2CSA 7G8 allele, in addition to isolates from South East Asia (M Camp), East Africa (M0736), and West Africa (NF54, M2022170, M2001190), thus representing geographically diverse origins. Overall, it may be difficult to estimate the fraction of variant-specific or cross-reactive antibodies contributed by each variant to the measured activities, knowing that each sequence of VAR2CSA could have multiple epitopes that are variably shared with some or all variants (Benavente et al., 2018; Otto et al., 2019). However, highly cross-reactive antibodies can be purified from a single recombinant VAR2CSA ectodomain, suggesting that immunization with a single variant may prove highly effective.

The full-length VAR2CSA ectodomain-based vaccine approach has been previously investigated in preclinical studies in which antisera raised in rodent models had strong homologous functional activity (Khunrae et al., 2010). However, these antibodies generated in rodents did not cross-inhibit different CSA-binding isolates, while exhibiting a broadly strain-transcending surface reactivity to these isolates (Avril et al., 2011). In contrast to this observation, our data demonstrate that naturally acquired IgG specific to a single variant and purified from multigravidae sera cross-inhibited multiple isolates. Notably, most of the binding-inhibition activity to CSA-binding parasites was depleted on the first variant and the resulting IgG purified on NF54 (in the first experiment) or M. Camp (in the second experiment) demonstrated strain-transcending blocking activity to all isolates tested in this study. Antibody response to VAR2CSA may differ between species or may differ based on exposure to vaccine antigen or to natural infection. For example, recently published data demonstrated that naturally acquired PfEMP1-specific antibodies are strongly afucosylated, while immunization with a subunit (VAR2CSA) vaccine results in fully fucosylated specific IgG (Larsen et al., 2021). Future studies that investigate differences in the host immune response to VAR2CSA in human versus other species will also elucidate any discrepancies between the functional activity of human versus rodent antibody.

Our data support the idea that one VAR2CSA variant might induce antibody with broad functional activity, acknowledging the challenges in developing a full-length VAR2CSA-based vaccine (reviewed in Doritchamou et al., 2021), including the possibility that non-functional epitopes may interfere with the optimal functional antibody response. It is also possible that the flanking flexible arm composed of DBL5ɛ–6ɛ or DBL5ɛ–7ɛ (in some cases) may play a role in masking functional epitopes on the core (NTS-ID3) structure of VAR2CSA (Doritchamou et al., 2019; Ma et al., 2021). Although recombinant expression of full-length VAR2CSA may not be feasible for manufacturing, novel technologies such as mRNA vaccine platform (reviewed in Pardi et al., 2018) should be explored in future studies. To conclude, we report that naturally acquired antibody purified on VAR2CSA ectodomains exhibited strong strain-transcending surface reactivity and blocking activity to CSA-binding isolates. Interestingly, IgG purified against a single variant captured the bulk of strain-transcending IE reactivity and CSA-binding inhibition activity from total IgG of PM-resistant multigravidae. Therefore, the full-length VAR2CSA ectodomain appears to display both variant-specific and shared epitopes targeted by functional antibodies and as such, would be a credible alternative to the VAR2CSA subunit approach in PM vaccine development. Moreover, cross-reactive antibodies could result from both conserved linear epitopes and conformational (tertiary structure related) epitopes, and the human monoclonal antibody PAM1.4 (Barfod et al., 2007) provides strong evidence of the latter. Although such antibodies may contribute to the broadly neutralizing activity of VAR2CSA-specific IgG described in this study, quantifying their relative contribution will inform future PM vaccine development.

All data generated or analysed during this study are included in the manuscript and supporting file; source data files have been provided for all figures.

1. 1. Ataíde R
   2. Mwapasa V
   3. Molyneux ME
   4. Meshnick SR
   5. Rogerson SJ

   (2011) Antibodies that induce phagocytosis of malaria infected erythrocytes: effect of HIV infection and correlation with clinical outcomes

   PLOS ONE 6:e22491.

   https://doi.org/10.1371/journal.pone.0022491

   • PubMed
   • Google Scholar
2. 1. Avril M
   2. Hathaway MJ
   3. Srivastava A
   4. Dechavanne S
   5. Hommel M
   6. Beeson JG
   7. Smith JD
   8. Gamain B

   (2011) Antibodies to a full-length VAR2CSA immunogen are broadly strain-transcendent but do not cross-inhibit different placental-type parasite isolates

   PLOS ONE 6:e16622.

   https://doi.org/10.1371/journal.pone.0016622

   • PubMed
   • Google Scholar
3. 1. Barfod L
   2. Bernasconi NL
   3. Dahlbäck M
   4. Jarrossay D
   5. Andersen PH
   6. Salanti A
   7. Ofori MF
   8. Turner L
   9. Resende M
   10. Nielsen MA
   11. Theander TG
   12. Sallusto F
   13. Lanzavecchia A
   14. Hviid L

   (2007) Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA

   Molecular Microbiology 63:335–347.

   https://doi.org/10.1111/j.1365-2958.2006.05503.x

   • PubMed
   • Google Scholar
4. 1. Benavente ED
   2. Oresegun DR
   3. de Sessions PF
   4. Walker EM
   5. Roper C
   6. Dombrowski JG
   7. de Souza RM
   8. Marinho CRF
   9. Sutherland CJ
   10. Hibberd ML
   11. Mohareb F
   12. Baker DA
   13. Clark TG
   14. Campino S

   (2018) Global genetic diversity of var2csa in Plasmodium falciparum with implications for malaria in pregnancy and vaccine development

   Scientific Reports 8:15429.

   https://doi.org/10.1038/s41598-018-33767-3

   • PubMed
   • Google Scholar
5. 1. Bertin GI
   2. Sabbagh A
   3. Guillonneau F
   4. Jafari-Guemouri S
   5. Ezinmegnon S
   6. Federici C
   7. Hounkpatin B
   8. Fievet N
   9. Deloron P

   (2013) Differential protein expression profiles between Plasmodium falciparum parasites isolated from subjects presenting with pregnancy-associated malaria and uncomplicated malaria in Benin

   The Journal of Infectious Diseases 208:1987–1997.

   https://doi.org/10.1093/infdis/jit377

   • PubMed
   • Google Scholar
6. 1. Bigey P
   2. Gnidehou S
   3. Doritchamou J
   4. Quiviger M
   5. Viwami F
   6. Couturier A
   7. Salanti A
   8. Nielsen MA
   9. Scherman D
   10. Deloron P
   11. Tuikue Ndam N

   (2011) The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A

   The Journal of Infectious Diseases 204:1125–1133.

   https://doi.org/10.1093/infdis/jir499

   • PubMed
   • Google Scholar
7. 1. Brabin BJ

   (1983)

   An analysis of malaria in pregnancy in Africa

   Bulletin of the World Health Organization 61:1005–1016.

   • PubMed
   • Google Scholar
8. 1. Chêne A
   2. Gangnard S
   3. Dechavanne C
   4. Dechavanne S
   5. Srivastava A
   6. Tétard M
   7. Hundt S
   8. Leroy O
   9. Havelange N
   10. Viebig NK
   11. Gamain B

   (2018) Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development

   NPJ Vaccines 3:28.

   https://doi.org/10.1038/s41541-018-0064-6

   • PubMed
   • Google Scholar
9. 1. Clausen TM
   2. Christoffersen S
   3. Dahlbäck M
   4. Langkilde AE
   5. Jensen KE
   6. Resende M
   7. Agerbæk MØ
   8. Andersen D
   9. Berisha B
   10. Ditlev SB
   11. Pinto VV
   12. Nielsen MA
   13. Theander TG
   14. Larsen S
   15. Salanti A

   (2012) Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria

   The Journal of Biological Chemistry 287:23332–23345.

   https://doi.org/10.1074/jbc.M112.348839

   • PubMed
   • Google Scholar
10. 1. Dahlbäck M
    2. Jørgensen LM
    3. Nielsen MA
    4. Clausen TM
    5. Ditlev SB
    6. Resende M
    7. Pinto VV
    8. Arnot DE
    9. Theander TG
    10. Salanti A

    (2011) The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domains

    The Journal of Biological Chemistry 286:15908–15917.

    https://doi.org/10.1074/jbc.M110.191510

    • PubMed
    • Google Scholar
11. 1. Desai M
    2. ter Kuile FO
    3. Nosten F
    4. McGready R
    5. Asamoa K
    6. Brabin B
    7. Newman RD

    (2007) Epidemiology and burden of malaria in pregnancy

    The Lancet. Infectious Diseases 7:93–104.

    https://doi.org/10.1016/S1473-3099(07)70021-X

    • PubMed
    • Google Scholar
12. 1. Doritchamou JYA
    2. Herrera R
    3. Aebig JA
    4. Morrison R
    5. Nguyen V
    6. Reiter K
    7. Shimp RL
    8. MacDonald NJ
    9. Narum DL
    10. Fried M
    11. Duffy PE

    (2016) VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria

    The Journal of Infectious Diseases 214:577–586.

    https://doi.org/10.1093/infdis/jiw197

    • PubMed
    • Google Scholar
13. 1. Doritchamou JYA
    2. Morrison R
    3. Renn JP
    4. Ribeiro J
    5. Duan J
    6. Fried M
    7. Duffy PE

    (2019) Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some Plasmodium falciparum strains

    Communications Biology 2:457.

    https://doi.org/10.1038/s42003-019-0704-z

    • PubMed
    • Google Scholar
14. 1. Doritchamou JYA
    2. Suurbaar J
    3. Tuikue Ndam N

    (2021) Progress and new horizons toward a VAR2CSA-based placental malaria vaccine

    Expert Review of Vaccines 20:215–226.

    https://doi.org/10.1080/14760584.2021.1878029

    • PubMed
    • Google Scholar
15. 1. Duffy PE
    2. Fried M

    (2003) Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns

    Infection and Immunity 71:6620–6623.

    https://doi.org/10.1128/IAI.71.11.6620-6623.2003

    • PubMed
    • Google Scholar
16. 1. Francis SE
    2. Malkov VA
    3. Oleinikov AV
    4. Rossnagle E
    5. Wendler JP
    6. Mutabingwa TK
    7. Fried M
    8. Duffy PE

    (2007) Six genes are preferentially transcribed by the circulating and sequestered forms of Plasmodium falciparum parasites that infect pregnant women

    Infection and Immunity 75:4838–4850.

    https://doi.org/10.1128/IAI.00635-07

    • PubMed
    • Google Scholar
17. 1. Fried M
    2. Duffy PE

    (1996) Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta

    Science (New York, N.Y.) 272:1502–1504.

    https://doi.org/10.1126/science.272.5267.1502

    • PubMed
    • Google Scholar
18. 1. Fried M
    2. Duffy PE

    (1998) Maternal malaria and parasite adhesion

    Journal of Molecular Medicine (Berlin, Germany) 76:162–171.

    https://doi.org/10.1007/s001090050205

    • PubMed
    • Google Scholar
19. 1. Fried M
    2. Hixson KK
    3. Anderson L
    4. Ogata Y
    5. Mutabingwa TK
    6. Duffy PE

    (2007) The distinct proteome of placental malaria parasites

    Molecular and Biochemical Parasitology 155:57–65.

    https://doi.org/10.1016/j.molbiopara.2007.05.010

    • PubMed
    • Google Scholar
20. 1. Fried M
    2. Avril M
    3. Chaturvedi R
    4. Fernandez P
    5. Lograsso J
    6. Narum D
    7. Nielsen MA
    8. Oleinikov AV
    9. Resende M
    10. Salanti A
    11. Saveria T
    12. Williamson K
    13. Dicko A
    14. Scherf A
    15. Smith JD
    16. Theander TG
    17. Duffy PE

    (2013) Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria

    Infection and Immunity 81:487–495.

    https://doi.org/10.1128/IAI.01106-12

    • PubMed
    • Google Scholar
21. 1. Fried M
    2. Kurtis JD
    3. Swihart B
    4. Morrison R
    5. Pond-Tor S
    6. Barry A
    7. Sidibe Y
    8. Keita S
    9. Mahamar A
    10. Andemel N
    11. Attaher O
    12. Dembele AB
    13. Cisse KB
    14. Diarra BS
    15. Kanoute MB
    16. Narum DL
    17. Dicko A
    18. Duffy PE

    (2018) Antibody levels to recombinant VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and gravidity, but do not predict pregnancy outcomes

    Malaria Journal 17:106.

    https://doi.org/10.1186/s12936-018-2258-9

    • PubMed
    • Google Scholar
22. 1. Gardner MJ
    2. Hall N
    3. Fung E
    4. White O
    5. Berriman M
    6. Hyman RW
    7. Carlton JM
    8. Pain A
    9. Nelson KE
    10. Bowman S
    11. Paulsen IT
    12. James K
    13. Eisen JA
    14. Rutherford K
    15. Salzberg SL
    16. Craig A
    17. Kyes S
    18. Chan M-S
    19. Nene V
    20. Shallom SJ
    21. Suh B
    22. Peterson J
    23. Angiuoli S
    24. Pertea M
    25. Allen J
    26. Selengut J
    27. Haft D
    28. Mather MW
    29. Vaidya AB
    30. Martin DMA
    31. Fairlamb AH
    32. Fraunholz MJ
    33. Roos DS
    34. Ralph SA
    35. McFadden GI
    36. Cummings LM
    37. Subramanian GM
    38. Mungall C
    39. Venter JC
    40. Carucci DJ
    41. Hoffman SL
    42. Newbold C
    43. Davis RW
    44. Fraser CM
    45. Barrell B

    (2002) Genome sequence of the human malaria parasite Plasmodium falciparum

    Nature 419:498–511.

    https://doi.org/10.1038/nature01097

    • PubMed
    • Google Scholar
23. 1. Guyatt HL
    2. Snow RW

    (2001) Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa

    Transactions of the Royal Society of Tropical Medicine and Hygiene 95:569–576.

    https://doi.org/10.1016/s0035-9203(01)90082-3

    • PubMed
    • Google Scholar
24. 1. Hayton K
    2. Gaur D
    3. Liu A
    4. Takahashi J
    5. Henschen B
    6. Singh S
    7. Lambert L
    8. Furuya T
    9. Bouttenot R
    10. Doll M
    11. Nawaz F
    12. Mu J
    13. Jiang L
    14. Miller LH
    15. Wellems TE

    (2008) Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion

    Cell Host & Microbe 4:40–51.

    https://doi.org/10.1016/j.chom.2008.06.001

    • PubMed
    • Google Scholar
25. 1. Hviid L
    2. Jensen ATR

    (2015) PfEMP1 - A Parasite Protein Family of Key Importance in Plasmodium falciparum Malaria Immunity and Pathogenesis

    Advances in Parasitology 88:51–84.

    https://doi.org/10.1016/bs.apar.2015.02.004

    • PubMed
    • Google Scholar
26. 1. Keen J
    2. Serghides L
    3. Ayi K
    4. Patel SN
    5. Ayisi J
    6. van Eijk A
    7. Steketee R
    8. Udhayakumar V
    9. Kain KC

    (2007) HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites

    PLOS Medicine 4:e181.

    https://doi.org/10.1371/journal.pmed.0040181

    • PubMed
    • Google Scholar
27. 1. Khunrae P
    2. Dahlbäck M
    3. Nielsen MA
    4. Andersen G
    5. Ditlev SB
    6. Resende M
    7. Pinto VV
    8. Theander TG
    9. Higgins MK
    10. Salanti A

    (2010) Full-length recombinant Plasmodium falciparum VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-blocking antibodies

    Journal of Molecular Biology 397:826–834.

    https://doi.org/10.1016/j.jmb.2010.01.040

    • PubMed
    • Google Scholar
28. 1. Kraemer SM
    2. Smith JD

    (2006) A family affair: var genes, PfEMP1 binding, and malaria disease

    Current Opinion in Microbiology 9:374–380.

    https://doi.org/10.1016/j.mib.2006.06.006

    • PubMed
    • Google Scholar
29. 1. Larsen MD
    2. Lopez-Perez M
    3. Dickson EK
    4. Ampomah P
    5. Tuikue Ndam N
    6. Nouta J
    7. Koeleman CAM
    8. Ederveen ALH
    9. Mordmüller B
    10. Salanti A
    11. Nielsen MA
    12. Massougbodji A
    13. van der Schoot CE
    14. Ofori MF
    15. Wuhrer M
    16. Hviid L
    17. Vidarsson G

    (2021) Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination

    Nature Communications 12:5838.

    https://doi.org/10.1038/s41467-021-26118-w

    • PubMed
    • Google Scholar
30. 1. Ma R
    2. Lian T
    3. Huang R
    4. Renn JP
    5. Petersen JD
    6. Zimmerberg J
    7. Duffy PE
    8. Tolia NH

    (2021) Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA

    Nature Microbiology 6:380–391.

    https://doi.org/10.1038/s41564-020-00858-9

    • PubMed
    • Google Scholar
31. 1. Moore KA
    2. Simpson JA
    3. Scoullar MJL
    4. McGready R
    5. Fowkes FJI

    (2017) Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis

    The Lancet. Global Health 5:e1101–e1112.

    https://doi.org/10.1016/S2214-109X(17)30340-6

    • PubMed
    • Google Scholar
32. 1. Mordmüller B
    2. Sulyok M
    3. Egger-Adam D
    4. Resende M
    5. de Jongh WA
    6. Jensen MH
    7. Smedegaard HH
    8. Ditlev SB
    9. Soegaard M
    10. Poulsen L
    11. Dyring C
    12. Calle CL
    13. Knoblich A
    14. Ibáñez J
    15. Esen M
    16. Deloron P
    17. Ndam N
    18. Issifou S
    19. Houard S
    20. Howard RF
    21. Reed SG
    22. Leroy O
    23. Luty AJF
    24. Theander TG
    25. Kremsner PG
    26. Salanti A
    27. Nielsen MA

    (2019) First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria

    Clinical Infectious Diseases 69:1509–1516.

    https://doi.org/10.1093/cid/ciy1140

    • PubMed
    • Google Scholar
33. 1. Ndam NT
    2. Denoeud-Ndam L
    3. Doritchamou J
    4. Viwami F
    5. Salanti A
    6. Nielsen MA
    7. Fievet N
    8. Massougbodji A
    9. Luty AJF
    10. Deloron P

    (2015) Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin

    Emerging Infectious Diseases 21:813–823.

    https://doi.org/10.3201/eid2105.141626

    • PubMed
    • Google Scholar
34. Book

    1. Nielsen MA
    2. Salanti A

    (2015) High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites

    In: Vaughan A, editors. In Malaria Vaccines: Methods and Protocols. New York: Springer. pp. 241–253.

    https://doi.org/10.1007/978-1-4939-2815-6_20

    • PubMed
    • Google Scholar
35. 1. Otto TD
    2. Assefa SA
    3. Böhme U
    4. Sanders MJ
    5. Kwiatkowski D
    6. Berriman M
    7. Newbold C
    8. Pf3k consortium

    (2019) Evolutionary analysis of the most polymorphic gene family in falciparum malaria

    Wellcome Open Research 4:193.

    https://doi.org/10.12688/wellcomeopenres.15590.1

    • PubMed
    • Google Scholar
36. 1. Pardi N
    2. Hogan MJ
    3. Porter FW
    4. Weissman D

    (2018) mRNA vaccines - a new era in vaccinology

    Nature Reviews. Drug Discovery 17:261–279.

    https://doi.org/10.1038/nrd.2017.243

    • PubMed
    • Google Scholar
37. 1. Renn JP
    2. Doritchamou JYA
    3. Tentokam BCN
    4. Morrison RD
    5. Cowles MV
    6. Burkhardt M
    7. Ma R
    8. Tolia NH
    9. Fried M
    10. Duffy PE

    (2021) Allelic variants of full-length VAR2CSA, the placental malaria vaccine candidate, differ in antigenicity and receptor binding affinity

    Communications Biology 4:1309.

    https://doi.org/10.1038/s42003-021-02787-7

    • PubMed
    • Google Scholar
38. 1. Ricke CH
    2. Staalsoe T
    3. Koram K
    4. Akanmori BD
    5. Riley EM
    6. Theander TG
    7. Hviid L

    (2000) Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A

    Journal of Immunology (Baltimore, Md 165:3309–3316.

    https://doi.org/10.4049/jimmunol.165.6.3309

    • PubMed
    • Google Scholar
39. 1. Salanti A
    2. Staalsoe T
    3. Lavstsen T
    4. Jensen ATR
    5. Sowa MPK
    6. Arnot DE
    7. Hviid L
    8. Theander TG

    (2003) Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria

    Molecular Microbiology 49:179–191.

    https://doi.org/10.1046/j.1365-2958.2003.03570.x

    • PubMed
    • Google Scholar
40. 1. Salanti A
    2. Dahlbäck M
    3. Turner L
    4. Nielsen MA
    5. Barfod L
    6. Magistrado P
    7. Jensen ATR
    8. Lavstsen T
    9. Ofori MF
    10. Marsh K
    11. Hviid L
    12. Theander TG

    (2004) Evidence for the involvement of VAR2CSA in pregnancy-associated malaria

    The Journal of Experimental Medicine 200:1197–1203.

    https://doi.org/10.1084/jem.20041579

    • PubMed
    • Google Scholar
41. 1. Sirima SB
    2. Richert L
    3. Chêne A
    4. Konate AT
    5. Campion C
    6. Dechavanne S
    7. Semblat JP
    8. Benhamouda N
    9. Bahuaud M
    10. Loulergue P
    11. Ouédraogo A
    12. Nébié I
    13. Kabore M
    14. Kargougou D
    15. Barry A
    16. Ouattara SM
    17. Boilet V
    18. Allais F
    19. Roguet G
    20. Havelange N
    21. Lopez-Perez E
    22. Kuppers A
    23. Konaté E
    24. Roussillon C
    25. Kanté M
    26. Belarbi L
    27. Diarra A
    28. Henry N
    29. Soulama I
    30. Ouédraogo A
    31. Esperou H
    32. Leroy O
    33. Batteux F
    34. Tartour E
    35. Viebig NK
    36. Thiebaut R
    37. Launay O
    38. Gamain B

    (2020) PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

    The Lancet. Infectious Diseases 20:585–597.

    https://doi.org/10.1016/S1473-3099(19)30739-X

    • PubMed
    • Google Scholar
42. 1. Steketee RW
    2. Nahlen BL
    3. Parise ME
    4. Menendez C

    (2001) The burden of malaria in pregnancy in malaria-endemic areas

    The American Journal of Tropical Medicine and Hygiene 64:28–35.

    https://doi.org/10.4269/ajtmh.2001.64.28

    • PubMed
    • Google Scholar
43. 1. Tuikue Ndam NG
    2. Salanti A
    3. Bertin G
    4. Dahlbäck M
    5. Fievet N
    6. Turner L
    7. Gaye A
    8. Theander T
    9. Deloron P

    (2005) High level of var2csa transcription by Plasmodium falciparum isolated from the placenta

    The Journal of Infectious Diseases 192:331–335.

    https://doi.org/10.1086/430933

    • PubMed
    • Google Scholar
44. 1. Tuikue Ndam N
    2. Bischoff E
    3. Proux C
    4. Lavstsen T
    5. Salanti A
    6. Guitard J
    7. Nielsen MA
    8. Coppée JY
    9. Gaye A
    10. Theander T
    11. David PH
    12. Deloron P

    (2008) Plasmodium falciparum transcriptome analysis reveals pregnancy malaria associated gene expression

    PLOS ONE 3:e1855.

    https://doi.org/10.1371/journal.pone.0001855

    • PubMed
    • Google Scholar
45. 1. Wang K
    2. Dagil R
    3. Lavstsen T
    4. Misra SK
    5. Spliid CB
    6. Wang Y
    7. Gustavsson T
    8. Sandoval DR
    9. Vidal-Calvo EE
    10. Choudhary S
    11. Agerbaek MØ
    12. Lindorff-Larsen K
    13. Nielsen MA
    14. Theander TG
    15. Sharp JS
    16. Clausen TM
    17. Gourdon P
    18. Salanti A

    (2021) Cryo-EM reveals the architecture of placental malaria VAR2CSA and provides molecular insight into chondroitin sulfate binding

    Nature Communications 12:2956.

    https://doi.org/10.1038/s41467-021-23254-1

    • PubMed
    • Google Scholar

Decision letter after peer review:

[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]

Thank you for resubmitting the paper entitled "A single full-length VAR2CSA ectodomain variant purifies broadly neutralizing antibodies against placental malaria isolates" for further consideration by eLife. Your revised article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. We are sorry to say that we have decided that this submission will not be considered further for publication by eLife.

While all reviewers found your work of interesting to the community, they also agreed that the findings reported are too preliminary to fully justify the conclusions drawn. In particular, the lack of permutated depletion experiments was considering a critical shortcoming, and that substantial additional experimentation will be necessary to alleviate this concern and the other concerns raised and detailed below.

Reviewer #1:

This is a follow-up of a similar study by the same authors (Doritchamou, 2016). While they previously used recombinant single- and double-domain constructs of VAR2CSA to affinity-purify IgG from placental malaria-exposed multigravidae, they now employ full-length VAR2CSA ectodomain constructs. In contrast to the findings from their earlier study, the authors now report that affinity purification of IgG on full-length VAR2CSA yielded IgG that contained broadly neutralizing (adhesion-blocking) activity. The study reports what appears to be essentially a single sequential experiment that is consistent with the authors' interpretation, but in my opinion falls somewhat short of fully justifying it.

Reactivity and neutralization data of experiments all variants and single variant-depleted and single variant-purified IgG would strengthen the study markedly. Furthermore, it would be interesting to see results from experiments where the order of the sequential depletion was permutated. Finally, the authors should present absolute adhesion and adhesion inhibition data, as normalized data can be quite misleading (e.g., they can produce impressive adhesion inhibition data for a parasite line that shows almost no adhesiveness initially).

Specific comments:

– L. 15 ("…it is still unclear… epitopes"): The authors themselves have previously reported data supporting the existence of broadly cross-reactive IgG acquired in response to natural infection (Barfod et al. 2010).

– L. 25-8: I find this conclusion too categorical, considered the limited evidence (the above-mentioned "single" experiment and the fact that only a few maternal isolates – from the same study site and temporally related? – were tested).

– L. 41-2: Expression of VAR2CSA was not formally demonstrated in Fried 1998 or Ricke 2000 as both studies predate the discovery of VAR2CSA.

– L. 46-8 could deserve referencing – either original studies or a recent review (e.g., Hviid and Jensen 2015).

– L. 51-4: Suggest adding Wang et al. Nat Commun 2021.

– L. 54-8: Nine references seems a bit excessive here.

– L. 153-5 ("Although… NF54-IgG"): Why did the authors not test for IgG reactivity against native 7G8-VAR2CSA and HB3-VAR2CSA on the surface of IEs?

– L. 155ff ("As with ELISA… antigen"): How does this sentence fit with the fact that reactivity against 7G8-IEs was not tested?

Reviewer #2:

This work builds on both work from this team suggesting that antibodies to individual VAR2CSA domains do not show broad cross reactive neutralising activity, and on two phase 1 trials of vaccines based on the DBL2 domain of VAR2CSA and flanking sequences, which showed limited heterologous protection in in vitro studies. This work has led to the idea that it might be necessary to include a cocktail of key variants to produce a successful vaccine. The current authors instead investigated whether antibodies purified using the whole protein ectodomain were markers of potential heterologous protection, and find that this is the case.

Generally the experiments presented and the interpretations of the findings appear logical and consistent. The figures show that depletion of antibodies using one VAR2CSA variant decreases antibody reactivity to other variants by ELISA and that the more the plasma is depleted, the greater the loss of antibody reactivity. Broadly similar data are shown for the ability of plasma to inhibit adhesion of infected erythrocytes (IEs) to CSA, and for ability to recognise the IE surface using flow cytometry. The validation of their ELISA findings with live parasites is a strength of this study.

The results are consistent with the idea that immunity to a single VAR2CSA variant might be associated with a fairly broad range of cross-reactive antibody to different VAR2CSA isolates that might broadly protect against placental malaria. It is not presently clear whether production of such an antigen at scale for use in vaccines is a realistic possibility, and this challenge might be mentioned in the discussion. It is also not clear whether immunisation with a single variant would result cross reactive immunity (recognition of an antigen by antibodies being different to an antigens ability to elicit antibodies). The results contrast with the animal immunisation studies mentioned in the discussion; however, the authors do not clearly discuss why this may be the case.

Specific suggestions

Line 84-87: should this be "that are absent in 'individual' vaccine fragments"? As this study does not confirm that all vaccine fragments together do not contain epitopes.

Lines 105 and 113-114: The data presented in figures 2 are different to those in supplementary figure 1. Therefore, the results from Figures in the main file and supplement should be described separately.

Line 263-7: We are missing details of how the ectodomains were expressed. There is a reference to Renn et al., JEM 20210848P which may be a submitted manuscript. This information is important in understanding how the protein expression was evaluated for conformation and folding, as it appears tertiary or higher-level structural considerations are important for understanding the difference between this study and previous efforts using single domains.

Discussion: Could the authors comment on whether it is that they have used a more complete protein or whether it is the tertiary structure which results in the cross-reactive antibodies? Would the use of for example 6 fragments (making up the whole VAR2CSA) give a similar result?

Figure 2 A: what do the brackets and asterisk refer to?

Figure 2 C: There is a comment about "histogram without IgG" – what does this refer to? Does it refer to B rather than C?

Figure 2 D may be redundant as it can be derived from figure 2C.

Figure 3 X axis should not be VAR2CSA, it is antibody reactivity to IEs.

Line 179- should this be 'heterologous parasites' not homologous as it is clear that other purifications did indeed capture IgG that could block activity against heterologous parasite strains (though not at the same level as that of the first depletion).

Line 202: what is an 'invariant protein'?

Methods:

Line 279-281 More detail of the elution buffer is also needed as low pH can cause changes to antibody conformation that might alter protein binding.

Lines 290,298-9 please provide details of the reagents used including detection antibodies and SYBR.

How many times did plasma need to be passed through column before activity was deemed fully depleted?

Reviewer #3:

1) It has been shown in a previous work (in particular by the first author of this work), that despite exposure to several field P. falciparum isolates, multigravid women could nevertheless be susceptible to placental infections by certain rare parasite variants (resembling in their var2csa sequence to strain WRO80). The authors should have discussed their findings in relation to these very relevant observations from this previous study?

2) Including laboratory strains 7G8 and HB3 in the cellular testings (surface reactivity and binding inhibition) would have helped to substantiate the authors' conclusions. The same applies to parasite isolates M920 and M200101 from which the FL var2csa recombinants have been produced.

3) The order of filtration of the MG IgG pool on the antigens during depletion / purification steps seems decisive. If this order had been different would the authors have expected the same activity pattern of the purified antibodies? It would have been interesting to reproduce this experiment by reversing this order. Carrying out this experiment in my opinion would have further strengthened the study and better reflect the title chosen by the authors. One can wonder whether all the VAR2CSA variants used in this study would be functionally comparable in this operation, if not the title of this study would be better suited to IgG purified on the VAR2CSA variant of NF54, as the depletion / purification activity on this protein (first in the series) presents the least bias compared to the others used afterwards.

4) Despite these comments which could only further help improve this work if addressed, the content is already of definite interest and may be published or with some few modifications.

5) Adding a figure (even as a supplementary) that shows the dispersion or phylogenic relation between the 7 VAR2CSA sequences used in this work would have been a good added value, as this will inform about their relationship with the main variants (3D7, FCR3, 7G8, WRO80) and help to further interpret the results.

6) The total IgGs purified from the MG pool show a strong reactivity against the 7 recombinants VAR2CSA used as well as on the native protein of the cultured parasites. This surface reactivity of the pre-depletion IgG pool is surprisingly less on the strain NF54 (Figure 2B). In Figure 3 the affinity-purified IgGs on the NF54 antigen (the first in the chain of depletion/purification) also show strong reactivity against the 7 recombinants used as well as on the native protein of all the 6 parasites cultured, including NF54. The authors should explain or discuss this weak recognition of the pre-depletion pool on the NF54 parasite which contrasts with the inhibitory properties observed (Figure 2C)?

7) Authors should describe how the plasma pool was prepared. It would be helpful to clarify how many multigravid women have been used as donors? If they were selected it would be necessary to clarify on which criteria and if not why.

[Editors’ note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors’ response to the first round of review.]

Reviewer #1:

This is a follow-up of a similar study by the same authors (Doritchamou, 2016). While they previously used recombinant single- and double-domain constructs of VAR2CSA to affinity-purify IgG from placental malaria-exposed multigravidae, they now employ full-length VAR2CSA ectodomain constructs. In contrast to the findings from their earlier study, the authors now report that affinity purification of IgG on full-length VAR2CSA yielded IgG that contained broadly neutralizing (adhesion-blocking) activity. The study reports what appears to be essentially a single sequential experiment that is consistent with the authors' interpretation, but in my opinion falls somewhat short of fully justifying it.

In an additional set of experiments, we have now reproduced our findings in studies in which we changed the order of VAR2CSA antigens used for the sequential purification/depletion of IgG. Our data confirm that antibody purified on the first antigen exhibits broadly neutralizing activity, and this is not dependent on the VAR2CSA variant used for initial purification.

Reactivity and neutralization data of experiments all variants and single variant-depleted and single variant-purified IgG would strengthen the study markedly. Furthermore, it would be interesting to see results from experiments where the order of the sequential depletion was permutated. Finally, the authors should present absolute adhesion and adhesion inhibition data, as normalized data can be quite misleading (e.g., they can produce impressive adhesion inhibition data for a parasite line that shows almost no adhesiveness initially).

We thank the reviewer for these suggestions. Unfortunately, our lab does not have both 7G8 and HB3 isolates. However, in this revised manuscript, we have included data generated on WF12, a progeny of 7G8 X GB4 whose genome encodes the 7G8 VAR2CSA allele (Hayton et al., Cell Host Microbe 2008). We have provided detailed information on WF12 in Supplemental Figure S2. We have also permutated the order of antigens in a second sequential depletion experiment using full-length VAR2CSA (FV2) representing Malayan Camp (MCamp), with FCR3 and NF54 variants (in that order) for purification/depletion. In our additional data, we show that IgG purified on FV2 MCamp had the highest cross-reactivity and cross-inhibitory activity against recombinant FV2 variants as well as against native antigen expressed by MCamp, FCR3 and NF54 parasites (Figure 5). This finding is consistent with the pattern observed with IgG purified on NF54 variant in the first sequential depletion experiment in our original manuscript. We have provided average CSA binding level for the isolates used in the BIA experiments as Table S1.

– L. 25-8: I find this conclusion too categorical, considered the limited evidence (the above-mentioned "single" experiment and the fact that only a few maternal isolates – from the same study site and temporally related? – were tested).

As noted above, we have now generated new data, using a different order of FV2 variants for antibody purification/depletion on the multigravidae plasma pool, and depleting initially with a west African variant (NF54) in the first set of experiments and in the second set of experiments depleting initially with southeast Asian variant (M Camp). We have incorporated an additional parasite (that expresses the South American VAR2CSA 7G8 allele), in addition to the isolates from SE Asia (M Camp), east Africa (M0736) and west Africa (NF54, M2022170, M2001190) reported in the original manuscript. We believe that the additional data from the second sequential depletion experiment and the expanded set of parasites support our conclusions.

– L. 41-2: Expression of VAR2CSA was not formally demonstrated in Fried 1998 or Ricke 2000 as both studies predate the discovery of VAR2CSA.

These two references referred to antibodies that bind to placental IE. The sentence has been modified for clarity (lines 43-44).

– L. 46-8 could deserve referencing – either original studies or a recent review (e.g., Hviid and Jensen 2015).

As suggested, references have been added (lines 50-51).

– L. 51-4: Suggest adding Wang et al. Nat Commun 2021.

The suggested reference has been added (line 57).

– L. 153-5 ("Although… NF54-IgG"): Why did the authors not test for IgG reactivity against native 7G8-VAR2CSA and HB3-VAR2CSA on the surface of IEs?

As indicated above, our lab does not have both 7G8 and HB3 isolates. We have now tested the purified IgG on WF12, a progeny of 7G8 X GB4 that expresses the same native VAR2CSA as South American 7G8 parasite.

Reviewer #2:

This work builds on both work from this team suggesting that antibodies to individual VAR2CSA domains do not show broad cross reactive neutralising activity, and on two phase 1 trials of vaccines based on the DBL2 domain of VAR2CSA and flanking sequences, which showed limited heterologous protection in in vitro studies. This work has led to the idea that it might be necessary to include a cocktail of key variants to produce a successful vaccine. The current authors instead investigated whether antibodies purified using the whole protein ectodomain were markers of potential heterologous protection, and find that this is the case.

Generally the experiments presented and the interpretations of the findings appear logical and consistent. The figures show that depletion of antibodies using one VAR2CSA variant decreases antibody reactivity to other variants by ELISA and that the more the plasma is depleted, the greater the loss of antibody reactivity. Broadly similar data are shown for the ability of plasma to inhibit adhesion of infected erythrocytes (IEs) to CSA, and for ability to recognise the IE surface using flow cytometry. The validation of their ELISA findings with live parasites is a strength of this study.

The results are consistent with the idea that immunity to a single VAR2CSA variant might be associated with a fairly broad range of cross-reactive antibody to different VAR2CSA isolates that might broadly protect against placental malaria. It is not presently clear whether production of such an antigen at scale for use in vaccines is a realistic possibility, and this challenge might be mentioned in the discussion. It is also not clear whether immunisation with a single variant would result cross reactive immunity (recognition of an antigen by antibodies being different to an antigens ability to elicit antibodies). The results contrast with the animal immunisation studies mentioned in the discussion; however, the authors do not clearly discuss why this may be the case.

We thank the reviewer for these comments, and we have made revisions and clarifications to our manuscript to address them. We share the reviewer’s concern about the realistic possibility to produce such a large antigen at scale for use in vaccines. However, we believe the mRNA vaccine platform (among other advanced technologies) could be a feasible approach to explore and have discussed this in the revised manuscript (Lines 272-275). We also recognized the limitation of antibodies induced against FV2 in animals to display broadly neutralizing activity, similar to what is seen in naturally acquired immunity. It is possible that differences in host responses and context of the antigen may alter quality of immunity. For example, recently published data demonstrated that naturally acquired PfEMP1-specific antibodies are strongly afucosylated, while immunization with a subunit (VAR2CSA) vaccine results in fully fucosylated specific IgG (Larsen et al., 2021). This study provides new understanding of key differences in antibody features between natural- and vaccine-induced immunity. The Discussion section has been amended with this new observation in the revised manuscript (lines 258-264).

Lines 105 and 113-114: The data presented in figures 2 are different to those in supplementary figure 1. Therefore, the results from Figures in the main file and supplement should be described separately.

Figure 2 and Supplementary Figure S1 are both used to demonstrate depletion of reactivity to VAR2CSA antigens and parasites from total IgG. However, Supplementary Figure S1 shows reactivity after each individual antigen-specific IgG purification/depletion, while Figure 2 only displays the difference between Pre-depletion IgG versus IgG post-depletion by all variants used.

Line 263-7 We are missing details of how the ectodomains were expressed. There is a reference to Renn et al., JEM 20210848P which may be a submitted manuscript. This information is important in understanding how the protein expression was evaluated for conformation and folding, as it appears tertiary or higher-level structural considerations are important for understanding the difference between this study and previous efforts using single domains.

That is an interesting point, and the reference has been updated in this revised version of the manuscript. We cite our new publication (Renn et al., Comms Bio 2021, DOI : 10.1038/s42003-021-02787-7) that provides a detailed description of the expression and functional characterization of full length VAR2CSA ectodomain variants (lines 301-306).

Discussion: Could the authors comment on whether it is that they have used a more complete protein or whether it is the tertiary structure which results in the cross-reactive antibodies? Would the use of for example 6 fragments (making up the whole VAR2CSA) give a similar result?

At the current state of understanding, it appears that cross-reactive antibodies could result from both conserved linear epitopes and conformational (tertiary structure related) epitopes. The strain-transcending human monoclonal antibody PAM1.4 provides strong evidence of a strain-transcending antibody targeting conformational epitopes on full-length VAR2CSA (Barfod et al., 2007). Although such antibodies may be contributing to the broadly neutralizing activities of PM IgG described in this study, quantifying their level of contribution will certainly provide crucial data to inform PM vaccine development. Similarly, whether the use of the 6 individual domains (making up the entirety of the VAR2CSA ectodomain) will give a similar result remains to be explored. The Discussion has been amended accordingly (lines 281-286)

Line 202: what is an 'invariant protein'?

Here, an “invariant protein” refers to a highly conserved protein across different variants of P. falciparum encoded by a single-copy gene. For example, we have a new publication that describes such an invariant protein on the surface of CSA-binding IE (Keitany et al., J Infect Dis. doi: 10.1093/infdis/jiab550).

Reviewer #3:

1) It has been shown in a previous work (in particular by the first author of this work), that despite exposure to several field P. falciparum isolates, multigravid women could nevertheless be susceptible to placental infections by certain rare parasite variants (resembling in their var2csa sequence to strain WRO80). The authors should have discussed their findings in relation to these very relevant observations from this previous study?

We thank the reviewer for this comment. We have indicated in this manuscript and Renn et al., 2021 that the VAR2CSA sequence of M920 has a similar ID1 motif as WR80. Our data here show that IgG purified on the first FV2 variant significantly cross-reacted with the M920 variant of VAR2CSA. Unfortunately, the M920 isolate was not available to us to generate any surface reactivity and binding inhibition data. At this point, we believe that our interpretation should be limited to the observed ELISA cross-reactivity to a WR80-like VAR2CSA.

2) Including laboratory strains 7G8 and HB3 in the cellular testings (surface reactivity and binding inhibition) would have helped to substantiate the authors' conclusions. The same applies to parasite isolates M920 and M200101 from which the FL var2csa recombinants have been produced.

We do not have 7G8 and HB3 strains but have included data generated on WF12 (a progeny of 7G8 X GB4 that expresses the same VAR2CSA sequences as 7G8 (Hayton et al., Cell Host Microbe 2008)) in this revised version of the manuscript. We believe that data generated from maternal isolates M2022170 (Mali), M2001190 (Mali) and M0736 (Tanzania, for which no VAR2CSA) protein was produced, have provided reasonably similar findings (substantial reduction of reactivities and inhibition after depletion of IgG specific to multiple variants of VAR2CSA) as those from M920 (parasite not available) and M200101 (fails to maintain expression of VAR2CSA in culture) would have provided.

3) The order of filtration of the MG IgG pool on the antigens during depletion / purification steps seems decisive. If this order had been different would the authors have expected the same activity pattern of the purified antibodies? It would have been interesting to reproduce this experiment by reversing this order. Carrying out this experiment in my opinion would have further strengthened the study and better reflect the title chosen by the authors. One can wonder whether all the VAR2CSA variants used in this study would be functionally comparable in this operation, if not the title of this study would be better suited to IgG purified on the VAR2CSA variant of NF54, as the depletion / purification activity on this protein (first in the series) presents the least bias compared to the others used afterwards.

We thank the reviewer for this suggestion and have carried on generating similar data from a second series of sequential FV2 IgG purifications on MCamp, FCR3 and NF54 variants, in that order. This time, IgG first purified on MCamp (SE Asia variant) displayed the highest level of cross-reactivities and cross-inhibition activity, similar to what was seen in our original experiment with IgG purified first on NF54 (west African variant). These new data support the idea that different full-length VAR2CSA variants used as a first antigen to deplete/purify IgG from multigravidae will produce comparable functional activities as seen with NF54 and MCamp.

5) Adding a figure (even as a supplementary) that shows the dispersion or phylogenic relation between the 7 VAR2CSA sequences used in this work would have been a good added value, as this will inform about their relationship with the main variants (3D7, FCR3, 7G8, WRO80) and help to further interpret the results.

A larger phylogenic analysis of VAR2CSA sequences including the 7 variants that were expressed is reported in our newly published paper that described the expression of these FV2 recombinants (Renn et al., 2021). We have also provided a phylogenetic tree with all the 7 variants of FV2 used in this study as Supplemental Figure S7. The NTS-DBL6 version of M200101 (NTS-DBL7) VAR2CSA sequence has been also included here as reference.

6) The total IgGs purified from the MG pool show a strong reactivity against the 7 recombinants VAR2CSA used as well as on the native protein of the cultured parasites. This surface reactivity of the pre-depletion IgG pool is surprisingly less on the strain NF54 (Figure 2B). In Figure 3 the affinity-purified IgGs on the NF54 antigen (the first in the chain of depletion/purification) also show strong reactivity against the 7 recombinants used as well as on the native protein of all the 6 parasites cultured, including NF54. The authors should explain or discuss this weak recognition of the pre-depletion pool on the NF54 parasite which contrasts with the inhibitory properties observed (Figure 2C)?

The lower reactivity of the pre-depletion total IgG (used at 100ug/mL) compared to the antigen-specific IgG (used at 1ug/mL) could be explained by the low concentration of VAR2CSA-specific IgG in the total IgG. Indeed, based on the antibody yield in Table 1, NF54-specific IgG might represent 1/400 fraction of the total IgG. In a tentative extrapolation of the Flow data, a level of surface reactivity similar to that of NF54-specific IgG might be obtained if pre-depletion total IgG was used at 400ug/mL.

7) Authors should describe how the plasma pool was prepared. It would be helpful to clarify how many multigravid women have been used as donors? If they were selected it would be necessary to clarify on which criteria and if not why.

The plasma pools used in this study are fractions of two larger stocks prepared by pooling up to 500ul of plasma from 119 (first purification/depletion experiment) and 98 (second purification/depletion experiment) randomly selected multigravid women. We have now provided this detail in the revised manuscript.

Author details

1. Justin YA Doritchamou

   Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Investigation, Supervision, Validation, Visualization, Writing - original draft

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-4589-7216

2. Jonathan P Renn

   Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States

   Contribution

   Conceptualization, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

3. Bethany Jenkins

   Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States

   Contribution

   Formal analysis, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

4. Almahamoudou Mahamar

   Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali

   Contribution

   Writing – review and editing, Conducted the clinical study in Mali and provided samples used in the study

   Competing interests

   No competing interests declared

5. Alassane Dicko

   Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali

   Contribution

   Writing – review and editing, Conducted the clinical study in Mali and provided samples used in the study

   Competing interests

   No competing interests declared

6. Michal Fried

   Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States

   Contribution

   Funding acquisition, Supervision, Writing – review and editing

   Competing interests

   No competing interests declared

7. Patrick E Duffy

   Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States

   Contribution

   Conceptualization, Funding acquisition, Supervision, Writing – review and editing

   For correspondence

   patrick.duffy@nih.gov

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-4483-5005

• 964

  Page views

• 210

  Downloads

• 9

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.